Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment: Costs of Adverse Events in aRCC: Y. Chen et al.

Authors: Chen, Yan¹ (AUTHOR), Du, Ella X.¹ (AUTHOR) Ella.Du@analysisgroup.com, Sundar, Manasvi¹ (AUTHOR), Betts, Keith A.¹ (AUTHOR), Yin, Xin² (AUTHOR), Eiffert, Samantha² (AUTHOR), Beauchamp, Karen² (AUTHOR), Delgado, Andrew² (AUTHOR), Rosenblatt, Lisa² (AUTHOR)

Source: PharmacoEconomics - Open. Jan2025, Vol. 9 Issue 1, p125-136. 12p.

Subject Terms: *Cost control, Renal cell carcinoma, Nosology, Acute kidney failure, Protein-tyrosine kinase inhibitors, Progression-free survival

scDCA: deciphering the dominant cell communication assembly of downstream functional events from single-cell RNA-seq data.

Authors: Ji, Boya¹ (AUTHOR), Wang, Xiaoqi¹ (AUTHOR), Wang, Xiang² (AUTHOR), Xu, Liwen¹ (AUTHOR), Peng, Shaoliang¹ (AUTHOR)

Source: Briefings in Bioinformatics. Jan2025, Vol. 26 Issue 1, p1-14. 14p.

Subject Terms: Cell communication, Renal cell carcinoma, Gene expression, Cancer cells, Cancer invasiveness

Long-term outcomes and survival rates of renal cell carcinoma patients in Erbil, Iraq: a follow-up study.

Authors: Salih, Fahmi Mohammed¹ (AUTHOR) fzebary@yahoo.com, Omar, Sami Saleem^1,2,3 (AUTHOR) sami.saleem@live.com, Hamza, Hawro Taha⁴ (AUTHOR) hawro_hamza@yahoo.com, Namiq, Karez Sarbast⁴ (AUTHOR) karez_koyi85@yahoo.com, Ameen, Hana Rizgar Mohammed¹ (AUTHOR) hana.rizgar93@yahoo.com, Rasul, Kakil Ibrahim⁵ (AUTHOR) kakil1954@gmail.com, Ismael, Sherzad Ali⁶ (AUTHOR) sherzad.aismael@gmail.com

Source: BMC Cancer. 3/3/2025, Vol. 25 Issue 1, p1-8. 8p.

Subject Terms: *SURVIVAL rate, *RENAL cell carcinoma, *SURVIVAL analysis (Biometry), *ANTINEOPLASTIC agents, *EPITHELIAL cells

The correlation between serum sex hormone levels and clear cell renal cell carcinoma in male patients.

Authors: Yu, Zhongwei¹ (AUTHOR), Zhao, Chenhui¹ (AUTHOR), Yang, Anqing¹ (AUTHOR), Liu, Xi¹ (AUTHOR), Xia, Yu¹ (AUTHOR), Cui, Renjie¹ (AUTHOR), Xu, Yongzhi¹ (AUTHOR), Ma, Binbin¹ (AUTHOR), Huang, Tao¹ (AUTHOR) 1093560388@qq.com

Source: Scientific Reports. 3/1/2025, Vol. 15 Issue 1, p1-5. 5p.

Subject Terms: *CYSTIC kidney disease, *RENAL cell carcinoma, *STATISTICAL significance, *LOGISTIC regression analysis, *SEX hormones

Pseudocapsule thickness is positively associated with prognosis in patients with clear cell renal cell carcinoma.

Authors: Xi, Wei¹ (AUTHOR) xi.wei@zs-hospital.sh.cn, Hou, Yingyong² (AUTHOR), Hou, Jun² (AUTHOR), Guo, Jianming¹ (AUTHOR) guo.jianming@zs-hospital.sh.cn

Source: BMC Cancer. 2/17/2025, Vol. 25 Issue 1, p1-8. 8p.

Subject Terms: *RENAL cell carcinoma, *PROGRESSION-free survival, *OVERALL survival, *REFERENCE values, *REGRESSION analysis

Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Pathologic T3a Upstaging in Clinical T1 RCC.

Authors: Yin, Di^1,2 (AUTHOR) 18109714901@163.com, Wang, Keruo² (AUTHOR), Xu, Hongyi^1,2 (AUTHOR) xuhongyitmu@163.com, Guo, Yunfei^1,2 (AUTHOR) gelly52100@163.com, Qian, Baoxin³ (AUTHOR) qianbaoxin@huiyihuiying.com, Duan, Dengyi^1,2 (AUTHOR) d18875255938@163.com, Li, Yiming^1,2 (AUTHOR) 17853295805@163.com, Zhang, Wenyi^1,2 (AUTHOR) zhangwenyilucky@126.com, Li, Zhengyang^1,2 (AUTHOR) zy849312853@163.com, Zhao, Yang^1,2 (AUTHOR) yang.zhao@tmu.edu.cn

Source: Diagnostics (2075-4418). Feb2025, Vol. 15 Issue 4, p443. 15p.

Subject Terms: *FEATURE extraction, *RENAL cell carcinoma, *RADIOMICS, *DECISION making, *NOMOGRAPHY (Mathematics)

LCAT in Cancer Biology: Embracing Epigenetic Regulation, Immune Interactions, and Therapeutic Implications.

Authors: Gao, Manzhi^1,2 (AUTHOR), Zhang, Wentian^1,2 (AUTHOR), Li, Xinxin^1,2 (AUTHOR), Li, Sumin^1,2 (AUTHOR), Wang, Wenlan^1,2 (AUTHOR), Han, Peijun^1,2 (AUTHOR) peijunhan@fmmu.edu.cn

Source: International Journal of Molecular Sciences. Feb2025, Vol. 26 Issue 4, p1453. 25p.

Subject Terms: *DEVELOPMENTAL biology, *RENAL cell carcinoma, *PROGNOSIS, *TREATMENT effectiveness, *HIGH density lipoproteins

AMEND 2.0: module identification and multi-omic data integration with multiplex-heterogeneous graphs.

Authors: Boyd, Samuel S.¹ (AUTHOR) samsboyd21@gmail.com, Slawson, Chad^2,3,4 (AUTHOR), Thompson, Jeffrey A.^1,3 (AUTHOR)

Source: BMC Bioinformatics. 2/5/2025, Vol. 26 Issue 1, p1-29. 29p.

Subject Terms: *BIOLOGICAL networks, *RENAL cell carcinoma, *DATA integration, *RANDOM walks, *BIOLOGICAL systems

An unusual case of post-menopausal bleeding.

Authors: Purwar, Roli¹ (AUTHOR) purwarroli@gmail.com, Kanugonda, Jyothi¹ (AUTHOR) knjyothianand@gmail.com, Shukla, Mridula² (AUTHOR) drmridulashukla@gmail.com, Pandey, Manoj¹ (AUTHOR) mpandey66@bhu.ac.in

Source: World Journal of Surgical Oncology. 2/4/2025, Vol. 23 Issue 1, p1-6. 6p.

Subject Terms: *RENAL cell carcinoma, *RENAL veins, *UTERINE hemorrhage, *METASTASIS, *POSTMENOPAUSE

Computed tomography and magnetic resonance imaging characteristics of renal cell carcinoma: Differences between subtypes and clinical evaluation.

Authors: Baytok, Ahmet¹ (AUTHOR) drahmetbaytok@gmail.com, Ecer, Gökhan² (AUTHOR), Balasar, Mehmet³ (AUTHOR), Koplay, Mustafa⁴ (AUTHOR)

Source: Journal of Clinical Imaging Science. Feb2025, Issue 2, p1-14. 14p.

Subject Terms: *MAGNETIC resonance imaging, *RENAL cell carcinoma, *CONTRAST media, *KIDNEY tumors, *PROGNOSIS

First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland.

Authors: Peres, Tobias¹ (AUTHOR) tobias.peres@kssg.ch, Aeppli, Stefanie^1,2 (AUTHOR), Fischer, Stefanie¹ (AUTHOR), Hundsberger, Thomas¹ (AUTHOR), Rothermundt, Christian² (AUTHOR)

Source: Current Oncology. Feb2025, Vol. 32 Issue 2, p64. 10p.

Subject Terms: *VON Hippel-Lindau disease, *RENAL cell carcinoma, *HYPOXIA-inducible factors, *TREATMENT effectiveness, *ANTINEOPLASTIC agents, *NEUROENDOCRINE tumors, *SCIENTIFIC observation, *HEMANGIOBLASTOMAS

Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma.

Authors: Zhao, Yiqiao¹ (AUTHOR), Yang, Liang^1,2 (AUTHOR), Bai, Xiaojie¹ (AUTHOR), Du, Lu¹ (AUTHOR), Lai, Huan¹ (AUTHOR), Liu, Yiyang¹ (AUTHOR), Chen, Ping¹ (AUTHOR), DiSanto, Michael E.³ (AUTHOR), Zhang, Xinhua¹ (AUTHOR) zhangxinhuad@163.com

Source: Scientific Reports. 1/25/2025, Vol. 15 Issue 1, p1-14. 14p.

Subject Terms: *MEDICAL sciences, *RENAL cell carcinoma, *OVERALL survival, *CANCER invasiveness, *CELL lines

Endogenous peptide CBDP1 inhibits clear cell renal cell carcinoma progression by targeting USP5/YTHDF2/TRPM5 axis.

Authors: Zhang, Yang^1,2 (AUTHOR) zhangyang_med@163.com, Zhu, Wei¹ (AUTHOR) zhuwell2018@163.com, Tao, Ruijie² (AUTHOR) jerry19960518@163.com, Li, Weijian^3,4 (AUTHOR) ajian0728@163.com, Jiang, Chunming¹ (AUTHOR) guloujiang@sina.com, Yan, Xiang^2,5 (AUTHOR) yanxiang@zju.edu.cn

Source: Journal of Translational Medicine. 1/25/2025, Vol. 23 Issue 1, p1-18. 18p.

Subject Terms: *RENAL cell carcinoma, *PEPTIDES, *CATHEPSIN B, *WESTERN immunoblotting, *GENE expression

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations.

Authors: Kikuta, Masato¹ (AUTHOR) favourite.nightmare0806@gmail.com, Naito, Sei¹ (AUTHOR) seinaito@med.id.yamagata-u.ac.jp, Osawa, Takahiro² (AUTHOR) taka0573@med.hokudai.ac.jp, Numakura, Kazuyuki³ (AUTHOR) nqf38647@nifty.com, Narisawa, Takafumi¹ (AUTHOR) tnari_0623@yahoo.co.jp, Takai, Yuki¹ (AUTHOR) t0a8_r1o2@yahoo.co.jp, Yagi, Mayu¹ (AUTHOR) mayu11ism05@gmail.com, Sekine, Yuya³ (AUTHOR) ysekine.bs@gmail.com, Tokairin, Ojiro² (AUTHOR) yokui120092@gmail.com, Shinohara, Nobuo² (AUTHOR) nozomis@mbj.nifty.com, Habuchi, Tomonori³ (AUTHOR) thabuchi@doc.med.akita-u.ac.jp, Tsuchiya, Norihiko¹ (AUTHOR) ntsuchiya@med.id.yamagata-u.ac.jp

Source: BMC Cancer. 1/22/2025, Vol. 25, p1-12. 12p.

Subject Terms: *RENAL cell carcinoma, *PROGRESSION-free survival, *PROTEIN-tyrosine kinase inhibitors, *OVERALL survival, *SURVIVAL rate

High-throughput methylation sequencing reveals novel biomarkers for the early detection of renal cell carcinoma.

Authors: Guo, Wenhao^1,2 (AUTHOR), Chen, Weiwu^1,3 (AUTHOR), Zhang, Jie¹ (AUTHOR), Li, Mingzhe¹ (AUTHOR), Huang, Hongyuan⁴ (AUTHOR), Wang, Qian⁵ (AUTHOR), Fei, Xiaoyi⁵ (AUTHOR), Huang, Jian⁶ (AUTHOR), Zheng, Tongning⁷ (AUTHOR), Fan, Haobo^1,3 (AUTHOR), Wang, Yunfei⁵ (AUTHOR), Gu, Hongcang⁶ (AUTHOR) gu_hongcang@cmpt.ac.cn, Ding, Guoqing¹ (AUTHOR) 3196014@zju.edu.cn, Chen, Yicheng¹ (AUTHOR) chenyicheng@zju.edu.cn

Source: BMC Cancer. 1/16/2025, Vol. 25 Issue 1, p1-14. 14p.

Subject Terms: *RENAL cell carcinoma, *CELL-free DNA, *DNA methylation, *PROGNOSTIC models, *RANDOM forest algorithms

Diagnostic performance of CT for extrarenal fat invasion in renal cell carcinoma: a meta-analysis and systematic review.

Authors: Ma, Junchao¹ (AUTHOR), Yuan, Enyu¹ (AUTHOR), Feng, Shijian² (AUTHOR), Yao, Jin¹ (AUTHOR), He, Chunlei³ (AUTHOR), Chen, Yuntian¹ (AUTHOR) YtChen@wchscu.cn, Song, Bin^1,3 (AUTHOR) songlab_radiology@163.com

Source: Insights into Imaging. 1/15/2025, Vol. 16 Issue 1, p1-13. 13p.

Subject Terms: *RENAL cell carcinoma, *COMPUTED tomography, *FAT, *UROLOGISTS, *RADIOLOGISTS

Leveraging explainable AI and large-scale datasets for comprehensive classification of renal histologic types.

Authors: Moon, Seung Wan¹ (AUTHOR), Kim, Jisup² (AUTHOR), Kim, Young Jae^1,3 (AUTHOR), Kim, Sung Hyun⁴ (AUTHOR), An, Chi Sung⁵ (AUTHOR), Kim, Kwang Gi^1,3 (AUTHOR) kimkg@gachon.ac.kr, Jung, Chan Kwon^6,7 (AUTHOR) ckjung@catholic.ac.kr

Source: Scientific Reports. 1/11/2025, Vol. 15 Issue 1, p1-12. 12p.

Subject Terms: *RECEIVER operating characteristic curves, *RENAL cell carcinoma, *BENIGN tumors, *KIDNEY tumors, *MEDICAL sciences

CASP5 associated with PANoptosis promotes tumorigenesis and progression of clear cell renal cell carcinoma.

Authors: Yang, Kangkang¹ (AUTHOR), Wang, Yushuang² (AUTHOR), Jian, Yuli³ (AUTHOR), Wang, Bo² (AUTHOR), Du, Hao⁴ (AUTHOR), Xia, Yuqing⁵ (AUTHOR), Bi, Jianlei⁶ (AUTHOR), Guo, Meihua¹ (AUTHOR), Li, Zhi² (AUTHOR) postlizhi@126.com, Wang, Ning¹ (AUTHOR) ningwang1990328@163.com

Source: Cancer Cell International. 1/8/2025, Vol. 25 Issue 1, p1-15. 15p.

Subject Terms: *MEDICAL sciences, *RENAL cell carcinoma, *IMMUNE checkpoint inhibitors, *TUMOR microenvironment, *WESTERN immunoblotting

A retrospective single-center pilot study of the genetic background of the transplanted kidney.

Authors: Novotna, Anna¹ (AUTHOR), Horackova, Klara² (AUTHOR), Soukupova, Jana² (AUTHOR), Zemankova, Petra^2,3 (AUTHOR), Nehasil, Petr^2,3,4 (AUTHOR), Just, Pavel² (AUTHOR), Voska, Ludek⁵ (AUTHOR), Kleiblova, Petra^2,6 (AUTHOR), Rajnochova Bloudickova, Silvie¹ (AUTHOR) sibl@ikem.cz

Source: PLoS ONE. 1/8/2025, Vol. 20 Issue 1, p1-15. 15p.

Subject Terms: *RENAL cell carcinoma, *CANCER genes, *GENETIC testing, *GENE targeting, *NUCLEOTIDE sequencing

Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT).

Authors: Gajagowni, Saivaroon^1,2 (AUTHOR), Wang, Emily³ (AUTHOR), Wang, Jianbo⁴ (AUTHOR), Campbell, Matthew T.⁴ (AUTHOR), Siddiqui, Bilal A.⁴ (AUTHOR) basiddiqui@mdanderson.org, Mayordomo, Jose I. (AUTHOR) josemayordomo@hotmail.com

Source: Case Reports in Oncological Medicine. 1/6/2025, Vol. 2025, p1-5. 5p.

Subject Terms: *RENAL cell carcinoma, *HEMOPHAGOCYTIC lymphohistiocytosis, *IMMUNE checkpoint proteins, *MULTIPLE organ failure, *DIAGNOSIS